DRL jumps 3% after launching chest pain patch
It is one of the few stocks that have gained in 2020 and is up 34 per cent year-to-date.
By ETMarkets.com |
AP
Shares of Dr. Reddy's Laboratories jumped over 3 per cent in Wednesday's trade after the company launched authorized generic version of NitroDur (nitroglycerin) Transdermal Infusion System.
The drug is used to prevent attacks of chest pain (angina), however, Nitro-Dur will not treat an angina attack that has already begun.
The combined market for all Nitroglycerin Transdermal Patch products had US sales of around $14.7 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.
The company’s Nitroglycerin Transdermal Infusion System is available in four dosage strengths: 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count. NitroDur is a trademark of USpharma.
The stock was up 3.08 per cent at Rs 3,860 on BSE. It is one of the few stocks that have gained in 2020 and is up 34 per cent year-to-date.
The drug is used to prevent attacks of chest pain (angina), however, Nitro-Dur will not treat an angina attack that has already begun.
The combined market for all Nitroglycerin Transdermal Patch products had US sales of around $14.7 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.
The company’s Nitroglycerin Transdermal Infusion System is available in four dosage strengths: 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count. NitroDur is a trademark of USpharma.
The stock was up 3.08 per cent at Rs 3,860 on BSE. It is one of the few stocks that have gained in 2020 and is up 34 per cent year-to-date.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
